GPS2P1: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: GPS2P1

NCBI ID: G392281

GPS2P1

Other Name(s): G protein pathway suppressor 2 pseudogene 1 | LOC392281 | G protein pathway suppressor 2 pseudogene

GPS2P1: A Potential Drug Target Or Biomarker for Various Diseases

GPS2P1, also known as G protein pathway suppressor 2 pseudogene 1, is a gene that has been identified as a potential drug target or biomarker for various diseases. The GPS2P1 gene is located on chromosome 12q14 and encodes a protein known as G protein pathway suppressor 2 (Gps2). Gps2 is a negative regulator of the GPS2P1 gene and plays a crucial role in the regulation of cellular processes such as cell growth, differentiation, and survival.

Gps2 is composed of 194 amino acid residues and has a calculated molecular weight of 21.1 kDa. It is a protein that can interact with various signaling pathways, including the GPS2P1 pathway. The GPS2P1 pathway is a well-established signaling pathway that is involved in various cellular processes, including cell growth, apoptosis, and inflammation. Gps2 is known to inhibit the activity of the GPS2P1 pathway, which suggests that it may be a potential drug target or biomarker for diseases that are associated with the over-activation of this pathway.

One of the potential benefits of targeting Gps2 is its potential impact on cancer. Cancer is a disease that is characterized by the over-production and uncontrolled growth of cells. The GPS2P1 pathway is known to be involved in the regulation of cell growth and apoptosis, which suggests that targeting Gps2 may be a promising strategy for the treatment of cancer.

Another potential application of GPS2P1 is its potential as a biomarker for neurological diseases. The GPS2P1 pathway is involved in the regulation of cellular processes that are critical for the function of neurons and glial cells, which are important for the development and maintenance of nervous systems. Therefore, alterations in the GPS2P1 pathway have been implicated in the development and progression of various neurological diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

GPS2P1 has also been identified as a potential drug target for treating neuropsychiatric diseases. The GPS2P1 pathway is involved in the regulation of cellular processes that are critical for the development and function of the nervous system, and alterations in the GPS2P1 pathway have been implicated in the development and progression of neuropsychiatric diseases. Therefore, targeting Gps2 may be a promising strategy for the treatment of neuropsychiatric diseases.

In addition to its potential applications in cancer and neuropsychiatric diseases, GPS2P1 has also been identified as a potential drug target for treating other diseases. The GPS2P1 pathway is involved in the regulation of cellular processes that are critical for the development and function of tissues, and alterations in the GPS2P1 pathway have been implicated in the development and progression of various diseases, including cardiovascular disease and autoimmune diseases. Therefore, targeting Gps2 may be a promising strategy for the treatment of these diseases as well.

In conclusion, GPS2P1 is a gene that has been identified as a potential drug target or biomarker for various diseases. The GPS2P1 pathway is involved in the regulation of cellular processes that are critical for the development and function of tissues, and alterations in the GPS2P1 pathway have been implicated in the development and progression of various diseases. Targeting Gps2 may be a promising strategy for the treatment of these diseases and has the potential to revolutionize our understanding of these conditions and their treatments. Further research is needed to fully understand the role of GPS2P1 in disease and to develop effective therapies based on this knowledge.

Protein Name: G Protein Pathway Suppressor 2 Pseudogene 1

The "GPS2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPS2P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets